Last reviewed: May 14, 2026
Last updated: May 14, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Novo Nordisk manufactures semaglutide, the active ingredient in Wegovy, the first FDA-approved GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight with weight-related conditions. However, compounded semaglutide from licensed 503A pharmacies provides medically supervised alternatives at different price points.
Patients considering semaglutide deserve clarity on sourcing, regulatory standards, and how individual factors like metabolic markers and genetic predispositions may inform treatment suitability. Understanding these distinctions supports more confident conversations with qualified healthcare providers about personalized weight management options.
The Original Developer: Novo Nordisk and FDA-Approved Semaglutide
Novo Nordisk developed semaglutide as a GLP-1 receptor agonist originally for type 2 diabetes. The company obtained FDA approval for Wegovy in 2021 specifically for chronic weight management, representing the first such approval in this category in nearly two decades.
Novo Nordisk manufactures Wegovy at pharmaceutical facilities meeting strict FDA manufacturing standards. The brand version carries significant demand due to clinical efficacy data, though supply constraints and cost have driven patient interest in alternative sourcing pathways.
Compounded Semaglutide: Licensed Pharmacy Standards and Supply Models
Compounded semaglutide prepared by licensed 503A pharmacies offers a regulated alternative pathway under federal law. These pharmacies compound medications for individual patient prescriptions when prescriber requests include semaglutide formulations not commercially available or for cost accessibility.
| Supply Source |
Regulatory Framework |
Cost Range |
Key Consideration |
| Novo Nordisk Wegovy |
FDA-approved brand pharmaceutical |
$900–$1,500/month |
Clinical trial data; insurance coverage limited |
| Compounded 503A Semaglutide |
Licensed pharmacy compounding; prescriber-directed |
$149/mo |
Medically supervised; patient-specific formulation |
| Compounded Tirzepatide (dual GLP-1/GIP) |
Licensed pharmacy compounding; newer option |
$249/mo |
Dual mechanism; emerging clinical data |
| Generic alternatives (future) |
Not currently available; anticipated post-patent |
TBD |
Patent exclusivity expires 2031 |
Regulatory Pathways: Understanding 503A Compounding vs. Brand Pharmaceuticals
The FDA regulates compounded medications through 503A oversight, requiring state pharmacy licensure, quality standards, and prescriber authorization for individual patients. Compounded semaglutide is not FDA-approved as a drug product but operates under established compounding authority when prepared by licensed facilities.
Brand Wegovy undergoes rigorous pre-market clinical trials and manufacturing inspections as a pharmaceutical product. Both pathways require qualified prescriber oversight, but compounding offers flexibility for patient-specific dosing and access when supply or cost barriers exist.
Who Should Consider Semaglutide and How Provider Evaluation Matters
Semaglutide may be appropriate for adults with obesity (BMI ≥30) or overweight with weight-related conditions like hypertension or type 2 diabetes. Qualified healthcare providers assess medical history, contraindications, and individual metabolic factors before recommending initiation and dose adjustments.
Personal factors including past medication responses, family history of thyroid conditions, pancreatitis risk, and genetic predispositions in GLP-1 signaling pathways inform provider decision-making. A thorough clinical evaluation ensures semaglutide aligns with individual health goals and safety requirements.
How PlexusDx Supports a More Personalized Approach
PlexusDx's Precision Peptide Genetic Test may help provide context on individual predispositions in peptide pathway genes including GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313. These genetic variants relate to GLP-1 receptor sensitivity and metabolic regulation, though they predict predispositions rather than exact medication response and should be interpreted with a qualified healthcare provider.
The genetic test reveals how an individual's unique peptide pathway profile may inform conversations about GLP-1 treatment suitability. Understanding whether genetic factors suggest higher or lower baseline GLP-1 signaling capacity can support a more personalized treatment discussion, though genetics represent only one factor among clinical history, biomarkers, and lifestyle context.
When combined with clinical assessment by a healthcare provider, genetic insight into peptide pathways may strengthen treatment selection confidence. PlexusDx offers compounded semaglutide starting at $179/month from licensed 503A pharmacies, alongside genetic testing at $99 as an add-on or $298 standalone to support informed, individualized care conversations.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Who manufactures semaglutide for weight loss?
Novo Nordisk manufactures FDA-approved Wegovy. Licensed 503A compounding pharmacies also prepare compounded semaglutide under prescriber direction, offering regulated alternatives at lower costs.
What is the difference between brand Wegovy and compounded semaglutide?
Wegovy is FDA-approved by Novo Nordisk; compounded semaglutide is prepared by licensed pharmacies under prescriber orders. Both require medical supervision. Compounded options typically cost $149/mo versus Wegovy at $900+/month, though clinical trial data exists primarily for the brand.
Is compounded semaglutide from PlexusDx safe and regulated?
PlexusDx sources compounded semaglutide exclusively from licensed 503A pharmacies meeting state and federal standards. All formulations require a qualified prescriber, medical oversight, and patient monitoring. Compounding is a legal, regulated healthcare practice.
What should I know about semaglutide side effects before starting?
Common side effects include nausea, vomiting, and gastrointestinal changes, typically mild and dose-dependent. Serious risks include pancreatitis symptoms and thyroid concerns. A qualified provider reviews individual risk factors and monitors tolerability during treatment initiation and dose escalation.
How can the Precision Peptide Genetic Test help with semaglutide decisions?
The test reveals predispositions in GLP1R, GIPR, and MC4R gene variants that relate to GLP-1 signaling capacity. This may provide context for provider discussions about treatment fit, though genetics represent one factor alongside clinical history and metabolic assessment.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Safe is Semaglutide Compound? Understanding the Risks and Benefits
Considering Ozempic for 10 Pounds of Weight Loss? Essential Insights